|August 11, 2014|
|08:22 EDT||TXMD, RTRX||Retrophin CEO in scandal over Twitter use, TheStreet reports|
Retrophin has placed the company's social media activity on "lockdown" following questionable tweets from CEO Martin Shkreli, including one that seemed to hint at a Retrophin acquisition of an approved drug from a private company, reported TheStreet's Adam Feuerstein. The social media blackout also follows the discovery that employees were using Twitter aliases to promote Retrophin and pitch short-sale recommendations of other stocks, including a tweet that singled out TherapeuticsMD (TXMD), the report added. Reference Link
News For RTRX;TXMD From The Last 14 Days
|November 24, 2014|
|15:22 EDT||RTRX||Retrophin founder Shkreli sells 1.172M shares|
Martin Shkreli, the founder, former CEO and 10% shareholder of Retrophin, sold 1.172M shares of the company's stock in several transactions between November 14 and November 21 at prices ranging from about $8.23 to about $10.23, according to a regulatory filing.
|November 19, 2014|
|15:30 EDT||RTRX||Retrophin founder Shkreli selling stake to fund new company, Feuerstein says|
Martin Shkreli, the founder and former CEO of Retrophin, is selling his stake in the company as he tries to raise $50M of funding for a new company, Turing Pharma, reported TheStreet's Adam Feuerstein, citing sources. Reference Link
|November 18, 2014|
|07:37 EDT||TXMD||Stifel to hold a conference|
Subscribe for More Information
|November 17, 2014|
|08:06 EDT||RTRX||Retrophin names Laura Clague as CFO|
Subscribe for More Information
|November 13, 2014|
|18:40 EDT||RTRX||On The Fly: After Hours Movers |
UP AFTER EARNINGS: TubeMogul (TUBE), up 12.4%... Weibo (WB), up 3.2%... Nordstrom (JWN), up 3.1%. ALSO HIGHER: Geron (GERN), up 30.7% after announcing a global strategic collaboration with Janssen Biotech... Baker Hughes (BHI), up 16.2% following reports that the company is in talks to be acquired by Halliburton (HAL)... Halliburton is up 1.4%... Pandora (P), up 4% after announcing a conference call to discuss Web IV proceeding... AmerisourceBergen (ABC), up 1.1% after being awarded a $4.06B government contract. DOWN AFTER EARNINGS: Retrophin (RTRX), down 6.6%... Phoenix New Media (FENG), down 8.4%... Voxeljet AG (VJET), down 8.6%... Intrexon (XON), down 1.1%... Youku Tudou (YOKU), down 5.7%... Applied Materials (AMAT), down 2.5%. ALSO LOWER: Puma Biotechnology (PBYI), down 6.9% following PB272 Phase II Trial results... EnLink Midstream (ENLK), down 4.8% after filing to sell 10.5M common units representing limited partners.
|17:19 EDT||RTRX||Retrophin lowers FY14 revenue view to $26M-$29M from $30M-$35M|
Based on the slower than expected progress while initially bringing patients back on Thiola after the supply outage, Retrophin is revising its 2014 financial guidance. The company now expects full-year 2014 revenues to be between $26M and $29M, down from the previously listed range of $30M to $35M. The company is removing the previously stated 2015 financial guidance and will be providing new 2015 financial guidance when year-end financial results are reported, which will be its new standard of practice.
|17:16 EDT||RTRX||Retrophin reports Q3 EPS (53c) vs (20c) last year|
Net sales for the third quarter of 2014 were $8.3M from product sales of Chenodal, Thiola and Vecamyl. Retrophin reported no revenue for the third quarter of 2013.
|09:45 EDT||TXMD||NYSE reports issue affecting one NYSE MKT workstation|
The NYSE MKT cash equities market is currently experiencing an issue with one workstation affecting order processing and trade execution in nine symbols, it announced in a market status alert. The impacted symbols are Cornerstone Progressive Return Fund (CFP), Alpha Pro Tech (APT), Denison Mines (DNN), First Austrailian Prime Income Fund (FAX), iBio (IBIO), inTEST (INTT), Provectus (PVCT), TherapeuticsMD (TXMD) and Uranerz Energy (URZ). The NYSE MKT will issue a non-regulatory halt condition in the symbols and will not be trading these securities for the remainder of the day, it stated. Reference Link